Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
All day on July 22nd
Keynote Forum: The Global Journey of China’s Innovation Drugs
Stay tuned
Opening Ceremony
Welcome Remarks
Awards Ceremony: CPIC Innovation Awards & Global Collaboration Awards
TBD
Xiaoliang Xie:Academician, Chinese Academy of Sciences; Foreign Associate, US National Academy of Sciences; Director, Changping National Laboratory
BeOne Medicines' Global Innovation Journey
Lai Wang:President, Global Head of Research & Development, BeOne Medicines
Akeso's Global Breakthrough in Bispecific Antibody Therapeutics (TBD)
Michelle Xia:Founder, Chairwoman, President, and CEO of Akeso Biopharma
Fireside Chat: Biokin's Journey to Becoming an MNC
Yi Zhu(guest):Founder and Chairman, Biokin Pharmaceutical
Zengjiang Cheng (Moderator):Executive Chairman, CPIC; Founder & Chairman, TONACEA
Stefan Platz:SVP,Clinical Pharmacology & SafetySciences,BioPharmaceuticals R&D, AstraZeneca
GPHL's Strategy for Innovative Drug Development
Xiaojun Li:Chairman, Guangzhou Pharmaceutical Holdings Limited (GPHL)
Panel Discussion I: How China Efficiency Accelerates MNC Innovation
Yongkui Sun:Member, U.S. National Academy of Engineering; Director, Shanghai Center for Drug Discovery and Development
Qiyu Chen:Co-Chief Executive Officer, Fosun International
Xiaobin Wu:President and COO, BeOne Medicines
Hong Shen:Head of the China Innovation Center of Roche (CICoR); Senior Vice President, Roche
Kendra Rose:SVP and Global Head of BD&L - CGT, Cardiovascular and Immunology, Bayer Pharmaceuticals
Rogier Janssens:President, Merck China; Head of Life Science Business, Merck China
Michael Han:Chairman of the Management Committee, Fangda Partners
Global Life Sciences Deals and the Globalization of China's Innovative Drugs
Daniel Mathews:EY Global Life Science Sector Lead
Scaling Growth Through a World-Class CRDMO Platform
Zhisheng Chen:CEO, WuXi Biologics; Chairman, WuXi Vaccines; Chairman, WuXi XDC
Development and Commercialization of the World's First CAR-T Therapy for Solid Tumors
Zonghai Li:Founder, Chairman, CEO and CSO, CARsgen Therapeutics
Globalization Pathways for China's Biopharmaceutical Industry
Xun Zhu:Founding Chairman, TONACEA Pharmaceutical Elite Club
Analysis of New Trends in U.S. Pharmaceutical Regulation
Ruyi He:President, Shanghai Institute for Global Health Innovation
Panel Discussion II: China's Innovative Biopharma: The Next Five Years of Global Expansion
Huawei Qiu:Chairman, China Resources Sanjiu Medical & Pharmaceutical
Theresa Tse:Chairwoman of the Board, Sino Biopharmaceutical Limited
Junyou Ge:CEO, Kelun-Biotech
Jianmin Fang:CEO, RemeGen
Jian Ma:Co-founder and CEO, XtalPi
Panel Discussion III: How China's FIC/BIC Innovation Is Reshaping Global Treatment Guidelines
Jin Li:President, Shanghai GoBroad Cancer Hospital
Caicun Zhou:Director of Oncology Department, Shanghai East Hospital; President, International Association for the Study of Lung Cancer (IASLC)
Jun Ma:Director, Harbin Institute of Hematology & Oncology; Chairman of the Board of Supervisors, Chinese Society of Clinical Oncology (CSCO)
Lin Shen:Director, Department of Gastrointestinal Oncology, Peking University Cancer Hospital
Li Wang:SVP, Eli Lilly and Company; Head of Lilly China Drug Development and Medical Affairs Center
Panel Discussion IV: Emerging Trends in Global Innovation Investment for China's Biotech
Wilson Xu:Head of International Business, Healthcare Coverage, CITIC Securities
Lyu Mingfang: Founding Chairman of China Healthcare Industry Investment 50 Forum, Partner of FountainVest Partners, Former Chairman of Shanghai Pharmaceuticals Holding Co., Ltd.
Junfeng Wang:Co-Chief Investment Officer and Managing Director, Legend Capital
Yu Chen:Founder and Managing Partner, TCG Crossover (TCGX)
Sun Jialin: Deputy Director of the Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation Association, General Manager of GTJA Investment Group